Marshall Wace LLP Has $22.72 Million Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Marshall Wace LLP decreased its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 0.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 827,958 shares of the company’s stock after selling 5,278 shares during the period. Marshall Wace LLP’s holdings in BridgeBio Pharma were worth $22,719,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of BBIO. Principal Financial Group Inc. lifted its stake in shares of BridgeBio Pharma by 1.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company’s stock valued at $29,155,000 after purchasing an additional 19,978 shares during the period. Teacher Retirement System of Texas increased its holdings in BridgeBio Pharma by 28.6% in the fourth quarter. Teacher Retirement System of Texas now owns 36,208 shares of the company’s stock worth $994,000 after purchasing an additional 8,048 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of BridgeBio Pharma by 6.2% during the 4th quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company’s stock worth $413,738,000 after buying an additional 879,059 shares in the last quarter. Exome Asset Management LLC grew its position in shares of BridgeBio Pharma by 167.4% during the 3rd quarter. Exome Asset Management LLC now owns 211,000 shares of the company’s stock worth $5,372,000 after buying an additional 132,093 shares during the period. Finally, Barclays PLC increased its stake in shares of BridgeBio Pharma by 31.9% in the 3rd quarter. Barclays PLC now owns 545,008 shares of the company’s stock valued at $13,876,000 after acquiring an additional 131,743 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.

Insider Activity at BridgeBio Pharma

In related news, CEO Neil Kumar sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $36.87, for a total transaction of $2,765,250.00. Following the completion of the sale, the chief executive officer now owns 4,948,447 shares in the company, valued at approximately $182,449,240.89. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Andrea Ellis sold 30,000 shares of BridgeBio Pharma stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $34.05, for a total transaction of $1,021,500.00. Following the completion of the sale, the director now directly owns 12,000 shares in the company, valued at approximately $408,600. This represents a 71.43 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 9,694,739 shares of company stock valued at $327,308,651. 24.66% of the stock is owned by insiders.

BridgeBio Pharma Price Performance

BBIO opened at $33.87 on Friday. The firm’s fifty day moving average price is $33.79 and its two-hundred day moving average price is $30.11. The company has a market capitalization of $6.44 billion, a price-to-earnings ratio of -11.88 and a beta of 1.08. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to analyst estimates of $4.04 million. As a group, equities analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Scotiabank increased their target price on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Friday, February 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $95.00 target price on shares of BridgeBio Pharma in a research report on Friday, February 21st. Evercore ISI raised their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research note on Monday, December 23rd. Citigroup boosted their price objective on BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a report on Friday, February 21st. Finally, Redburn Atlantic started coverage on BridgeBio Pharma in a report on Monday, March 31st. They issued a “buy” rating and a $50.00 target price on the stock. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, BridgeBio Pharma has an average rating of “Moderate Buy” and an average price target of $53.00.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.